Surgalign has 45 days to avoid being delisted from Nasdaq, the company said April 14.
The company on April 10 recieved a notification from Nasdaq’s listing qualities department saying the company isn’t in compliance with the $10 million minimum stockholders’ equity requirement for listing, according to a news release.
The company has to submit a plan to regain compliance which may include an application to transger its common stock listing to the Nasdaq capital market. Surgalign plans to file documents on or before May 25 to regain compliance.
The highest-paid CEOs at spine and orthopedic medtech companies saw total compensation of more than $20 million. Here is how…
Elon Musk’s brain-implant company, Neuralink, may soon have a new competitor in the market. Neurotechnology startup Precision Neuroscience has earned…
Alphatec CEO Patrick Miles earned about $6.2 million in total compensation, according to the company’s April 11 Securities and Exchange…
Comments are closed.